Hayes Caroline, Wahba Mourad, Watson Stuart
Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, St Nicholas Hospital, Jubilee Road, Newcastle upon Tyne NE3 3XT, UK.
Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK.
Ther Adv Psychopharmacol. 2022 Apr 22;12:20451253221090822. doi: 10.1177/20451253221090822. eCollection 2022.
Psilocybin as a novel treatment for depression is garnering a lot of attention from both the mainstream media and the academic community. Although phase 3 trials are only just beginning, we feel that it is important for clinicians to consider what psilocybin-assisted psychotherapy might look like in the clinical setting. In this narrative review article we have considered the difficulties that may arise as psilocybin emerges from the research setting, which may hamper its progress towards becoming a licenced medication. Psilocybin has its own unique challenges: the expectation patients come to dosing with having read overwhelmingly positive media; patient suggestibility under the influence of psilocybin and requirement for specialised therapists to name a few. We have also made some recommendations for measures that should be taken in both the phase 3 trials and with clinicians to try and minimise some of the issues raised. In doing so our hope is that psilocybin will continue towards becoming a licenced medication that suitable patients are able to access with relative ease. Practicing psychiatrists need to have an awareness of the potential pitfalls of psilocybin as they will be responsible for prescribing it in the future.
裸盖菇素作为一种治疗抑郁症的新型药物正受到主流媒体和学术界的广泛关注。尽管三期试验才刚刚开始，但我们认为临床医生了解裸盖菇素辅助心理治疗在临床环境中的情况很重要。在这篇叙述性综述文章中，我们探讨了裸盖菇素走出研究环境后可能出现的困难，这些困难可能会阻碍其成为一种获批药物的进程。裸盖菇素有其独特的挑战：患者受大量正面媒体报道影响而产生的期望；裸盖菇素作用下患者的易受暗示性以及对专业治疗师的需求等等。我们还针对三期试验和临床医生应采取的措施提出了一些建议，以尽量减少所提出的一些问题。我们希望通过这样做，裸盖菇素能够继续朝着成为一种获批药物的方向发展，使合适的患者能够相对轻松地获得。执业精神科医生需要意识到裸盖菇素的潜在风险，因为他们未来将负责开具这种药物的处方。
